A selective review of medical cannabis in cancer pain management
Insufficient management of cancer-associated chronic and neuropathic pain adversely affects patient quality of life.
Insufficient management of cancer-associated chronic and neuropathic pain adversely affects patient quality of life.
Medical cannabis, or cannabinoid-based products, continues to grow in popularity globally, driving the evolution of regulatory access frameworks; cancer patients and caregivers often rely on guidance from their physicians regarding cannabinoid-based treatments.
Recently, many countries have enacted new cannabis policies, including decriminalization of cannabis possession as well as legalization of medical and recreational cannabis. In this context, patients and their physicians have had an increasing number of conversations about the risks and benefits of cannabis.
Minnesota’s medical cannabis program is unique, in that it routinely collects patient-reported scores on symptoms. This article focuses on changes in symptom severity reported by patients with cancer during their first 4 months of program participation.
The use of cannabis for medical purposes has been recently legalised in many countries including the Czech Republic.
Research on the patterns of use of medical cannabis among cancer patients is lacking. CBD; THC; cancer; cannabis; medical marijuana.
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain.
Lung cancer continues to be one of the most common causes of cancer death despite understanding the major cause of the disease: cigarette smoking.
Cannabis sativa has long been used for medicinal purposes.
The use of medical marijuana in cancer care presents a dilemma for both patients and physicians.